RxDoctor Payments Data

Lokesh Jha, MD

Gastroenterology · Fort Wayne, INNPI 1245439223

Payments from drug & device makers

$4,258in general payments, 2019–2025

Across 122 payments — averaging $34.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$389
  • Olympus America Inc.$377
  • AbbVie$255
  • Johnson & Johnson$246
  • Madrigal Pharmaceuticals$165
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$1,67739%
  • Food & beverage$2,53059%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,258 in reported general payments places this provider in the 60th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$48,913
Medicare patients
273
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide36$27,956
MotegrityPrucalopride Succinate18$14,643
Sucralfate62$4,229
Omeprazole348$4,051
Dexlansoprazole DrDexlansoprazole14$3,651
Rabeprazole Sodium45$2,538
Esomeprazole Magnesium29$2,078
Pantoprazole Sodium131$1,670
Famotidine87$1,545
Colestipol Hcl14$774
Baclofen57$659
Nystatin15$319
Hyoscyamine Sulfate12$161
Metronidazole16$156
Nortriptyline Hcl12$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$255$27,95636 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$389$14,64318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →